Pasithea Therapeutics' 2025 10-K Reveals $20.4M Net Loss, Widening from Previous Year
KTTA has more than doubled off its 52-week low of $0.281 on light trading volume (0.2× avg).
Summary
Pasithea Therapeutics reported a significant net loss of $20.428 million and an operating loss of $20.857 million for the year ended December 31, 2025, as disclosed in its 10-K filing. This net loss represents a substantial increase from the $13.905 million loss reported in 2024, primarily driven by higher general and administrative and research & development expenses. For a micro-cap company, these material losses highlight a considerable cash burn rate. While the company noted it raised significant equity in 2025 to provide a multi-year runway and is advancing its PAS-004 clinical program, the widening losses will be a key concern for investors. Traders will closely watch the company's cash position and future financing activities as it continues its clinical development.
At the time of this announcement, KTTA was trading at $0.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.5M. The 52-week trading range was $0.28 to $3.79. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.